These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 26468509)

  • 1. The rational design of a gemcitabine prodrug with AIE-based intracellular light-up characteristics for selective suppression of pancreatic cancer cells.
    Han H; Jin Q; Wang Y; Chen Y; Ji J
    Chem Commun (Camb); 2015 Dec; 51(98):17435-8. PubMed ID: 26468509
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A cascade enzymatic reaction activatable gemcitabine prodrug with an AIE-based intracellular light-up apoptotic probe for in situ self-therapeutic monitoring.
    Han H; Teng W; Chen T; Zhao J; Jin Q; Qin Z; Ji J
    Chem Commun (Camb); 2017 Aug; 53(66):9214-9217. PubMed ID: 28766646
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A biocompatible and cathepsin B sensitive nanoscale system of dendritic polyHPMA-gemcitabine prodrug enhances antitumor activity markedly.
    Dai Y; Ma X; Zhang Y; Chen K; Tang JZ; Gong Q; Luo K
    Biomater Sci; 2018 Nov; 6(11):2976-2986. PubMed ID: 30255871
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Synthesis of Gemcitabine-Threonine Amide Prodrug Effective on Pancreatic Cancer Cells with Improved Pharmacokinetic Properties.
    Hong S; Fang Z; Jung HY; Yoon JH; Hong SS; Maeng HJ
    Molecules; 2018 Oct; 23(10):. PubMed ID: 30314360
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A Hydrogen Peroxide Activatable Gemcitabine Prodrug for the Selective Treatment of Pancreatic Ductal Adenocarcinoma.
    Matsushita K; Okuda T; Mori S; Konno M; Eguchi H; Asai A; Koseki J; Iwagami Y; Yamada D; Akita H; Asaoka T; Noda T; Kawamoto K; Gotoh K; Kobayashi S; Kasahara Y; Morihiro K; Satoh T; Doki Y; Mori M; Ishii H; Obika S
    ChemMedChem; 2019 Aug; 14(15):1384-1391. PubMed ID: 31207139
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Multifunctional Tumor-Targeting Cathepsin B-Sensitive Gemcitabine Prodrug Covalently Targets Albumin in Situ and Improves Cancer Therapy.
    Zhang H; Sun Z; Wang K; Li N; Chen H; Tan X; Li L; He Z; Sun J
    Bioconjug Chem; 2018 Jun; 29(6):1852-1858. PubMed ID: 29775284
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Nanomized tumor-microenvironment-active NIR fluorescent prodrug for ensuring synchronous occurrences of drug release and fluorescence tracing.
    Li Q; Cao J; Wang Q; Zhang J; Zhu S; Guo Z; Zhu WH
    J Mater Chem B; 2019 Mar; 7(9):1503-1509. PubMed ID: 32255021
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Enhanced cellular uptake and intracellular drug controlled release of VESylated gemcitabine prodrug nanocapsules.
    Fang Y; Du F; Xu Y; Meng H; Huang J; Zhang X; Lu W; Liu S; Yu J
    Colloids Surf B Biointerfaces; 2015 Apr; 128():357-362. PubMed ID: 25746328
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Biomimetic Gemcitabine-Lipid Prodrug Nanoparticles for Pancreatic Cancer.
    Bulanadi JC; Xue A; Gong X; Bean PA; Julovi SM; de Campo L; Smith RC; Moghaddam MJ
    Chempluschem; 2020 Jun; 85(6):1283-1291. PubMed ID: 32543086
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Theranostic reduction-sensitive gemcitabine prodrug micelles for near-infrared imaging and pancreatic cancer therapy.
    Han H; Wang H; Chen Y; Li Z; Wang Y; Jin Q; Ji J
    Nanoscale; 2016 Jan; 8(1):283-91. PubMed ID: 26608864
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Hyaluronic acid-coated, prodrug-based nanostructured lipid carriers for enhanced pancreatic cancer therapy.
    Lu Z; Su J; Li Z; Zhan Y; Ye D
    Drug Dev Ind Pharm; 2017 Jan; 43(1):160-170. PubMed ID: 27553814
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Enzyme-sensitive gemcitabine conjugated albumin nanoparticles as a versatile theranostic nanoplatform for pancreatic cancer treatment.
    Han H; Wang J; Chen T; Yin L; Jin Q; Ji J
    J Colloid Interface Sci; 2017 Dec; 507():217-224. PubMed ID: 28800445
    [TBL] [Abstract][Full Text] [Related]  

  • 13. One-step preparation of reduction-responsive cross-linked gemcitabine prodrug micelles for intracellular drug delivery.
    Chen X; Teng W; Jin Q; Ji J
    Colloids Surf B Biointerfaces; 2019 Sep; 181():94-101. PubMed ID: 31125923
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Potential Development of Tumor-Targeted Oral Anti-Cancer Prodrugs: Amino Acid and Dipeptide Monoester Prodrugs of Gemcitabine.
    Tsume Y; Drelich AJ; Smith DE; Amidon GL
    Molecules; 2017 Aug; 22(8):. PubMed ID: 28796151
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Self-Assembled Gemcitabine Prodrug Nanoparticles Show Enhanced Efficacy against Patient-Derived Pancreatic Ductal Adenocarcinoma.
    Wu L; Zhang F; Chen X; Wan J; Wang Y; Li T; Wang H
    ACS Appl Mater Interfaces; 2020 Jan; 12(3):3327-3340. PubMed ID: 31872760
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A fluorescence off-on reporter for real time monitoring of gemcitabine delivery to the cancer cells.
    Bhuniya S; Lee MH; Jeon HM; Han JH; Lee JH; Park N; Maiti S; Kang C; Kim JS
    Chem Commun (Camb); 2013 Aug; 49(64):7141-3. PubMed ID: 23831834
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dual Enzymatic Reaction-Assisted Gemcitabine Delivery Systems for Programmed Pancreatic Cancer Therapy.
    Han H; Valdepérez D; Jin Q; Yang B; Li Z; Wu Y; Pelaz B; Parak WJ; Ji J
    ACS Nano; 2017 Feb; 11(2):1281-1291. PubMed ID: 28071891
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficient Click Synthesis of a Protonized and Reduction-Sensitive Amphiphilic Small-Molecule Prodrug Containing Camptothecin and Gemcitabine for a Drug Self-Delivery System.
    Dong S; He J; Sun Y; Li D; Li L; Zhang M; Ni P
    Mol Pharm; 2019 Sep; 16(9):3770-3779. PubMed ID: 31348660
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Gemcitabine-based therapy for pancreatic cancer using the squalenoyl nucleoside monophosphate nanoassemblies.
    Maksimenko A; Caron J; Mougin J; Desmaële D; Couvreur P
    Int J Pharm; 2015 Mar; 482(1-2):38-46. PubMed ID: 25448549
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Carrier-free Janus nano-prodrug based on camptothecin and gemcitabine: Reduction-triggered drug release and synergistic in vitro antiproliferative effect in multiple cancer cells.
    Xu Y; Huang Y; Zhang X; Lu W; Yu J; Liu S
    Int J Pharm; 2018 Oct; 550(1-2):45-56. PubMed ID: 30138703
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.